192 related articles for article (PubMed ID: 24367180)
1. Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer.
Menis J; Twelves C
Breast Cancer (Dove Med Press); 2011 Aug; 3():101-11. PubMed ID: 24367180
[TBL] [Abstract][Full Text] [Related]
2. Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.
Scarpace SL
Clin Ther; 2012 Jul; 34(7):1467-73. PubMed ID: 22739019
[TBL] [Abstract][Full Text] [Related]
3. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.
Cortes J; O'Shaughnessy J; Loesch D; Blum JL; Vahdat LT; Petrakova K; Chollet P; Manikas A; Diéras V; Delozier T; Vladimirov V; Cardoso F; Koh H; Bougnoux P; Dutcus CE; Seegobin S; Mir D; Meneses N; Wanders J; Twelves C;
Lancet; 2011 Mar; 377(9769):914-23. PubMed ID: 21376385
[TBL] [Abstract][Full Text] [Related]
4. Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer.
McBride A; Butler SK
Am J Health Syst Pharm; 2012 May; 69(9):745-55. PubMed ID: 22517020
[TBL] [Abstract][Full Text] [Related]
5. Review on the clinical use of eribulin mesylate for the treatment of breast cancer.
Aseyev O; Ribeiro JM; Cardoso F
Expert Opin Pharmacother; 2016; 17(4):589-600. PubMed ID: 26809667
[TBL] [Abstract][Full Text] [Related]
6. Eribulin mesylate for the treatment of late-stage breast cancer.
Gourmelon C; Frenel JS; Campone M
Expert Opin Pharmacother; 2011 Dec; 12(18):2883-90. PubMed ID: 22087618
[TBL] [Abstract][Full Text] [Related]
7. Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions.
Towle MJ; Nomoto K; Asano M; Kishi Y; Yu MJ; Littlefield BA
Anticancer Res; 2012 May; 32(5):1611-9. PubMed ID: 22593439
[TBL] [Abstract][Full Text] [Related]
8. Eribulin mesylate (Halaven) for breast cancer.
Med Lett Drugs Ther; 2011 Apr; 53(1362):30-1. PubMed ID: 21502935
[TBL] [Abstract][Full Text] [Related]
9. Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies.
O'Shaughnessy J; McIntyre K; Schwartzberg L; Wilks S; Puhalla S; Berrak E; Song J; Vahdat L
Springerplus; 2015; 4():532. PubMed ID: 26413438
[TBL] [Abstract][Full Text] [Related]
10. Eribulin: a novel cytotoxic chemotherapy agent.
Preston JN; Trivedi MV
Ann Pharmacother; 2012 Jun; 46(6):802-11. PubMed ID: 22619477
[TBL] [Abstract][Full Text] [Related]
11. Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective study.
Zhao Y; Xie N; Li W; Chen W; Lv Z; Zheng Y; Sun T; Liu J; Zhang J; Hu S; Wang Y; Gong C; Li Y; Xie Y; Ge R; Xu F; Wang B
Ther Adv Med Oncol; 2021; 13():17588359211030210. PubMed ID: 34290830
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer.
O'Sullivan Coyne G; Walsh J; Kelly CM
Expert Opin Drug Saf; 2012 Jul; 11(4):643-50. PubMed ID: 22694309
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.
Cortes J; Vahdat L; Blum JL; Twelves C; Campone M; Roché H; Bachelot T; Awada A; Paridaens R; Goncalves A; Shuster DE; Wanders J; Fang F; Gurnani R; Richmond E; Cole PE; Ashworth S; Allison MA
J Clin Oncol; 2010 Sep; 28(25):3922-8. PubMed ID: 20679609
[TBL] [Abstract][Full Text] [Related]
14. A comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting.
Dranitsaris G; Beegle N; Kalberer T; Blau S; Cox D; Faria C
J Oncol Pharm Pract; 2015 Jun; 21(3):170-7. PubMed ID: 24620009
[TBL] [Abstract][Full Text] [Related]
15. Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer.
Muñoz-Couselo E; Pérez-García J; Cortés J
Onco Targets Ther; 2011; 4():185-92. PubMed ID: 22162924
[TBL] [Abstract][Full Text] [Related]
16. Eribulin in the management of inoperable soft-tissue sarcoma: patient selection and survival.
Thomas C; Movva S
Onco Targets Ther; 2016; 9():5619-27. PubMed ID: 27672333
[TBL] [Abstract][Full Text] [Related]
17. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer.
Twelves C; Cortes J; Vahdat LT; Wanders J; Akerele C; Kaufman PA
Clin Breast Cancer; 2010 Apr; 10(2):160-3. PubMed ID: 20299316
[TBL] [Abstract][Full Text] [Related]
18. Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy.
Doherty MK; Morris PG
Int J Womens Health; 2015; 7():47-58. PubMed ID: 25610001
[TBL] [Abstract][Full Text] [Related]
19. The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use.
Pean E; Klaar S; Berglund EG; Salmonson T; Borregaard J; Hofland KF; Ersbøll J; Abadie E; Giuliani R; Pignatti F
Clin Cancer Res; 2012 Sep; 18(17):4491-7. PubMed ID: 22829199
[TBL] [Abstract][Full Text] [Related]
20. Eribulin mesylate: a promising new antineoplastic agent for locally advanced or metastatic breast cancer.
Cortes J; Lorca R
Future Oncol; 2011 Mar; 7(3):355-64. PubMed ID: 21375468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]